AEON Biopharma, Inc. Class A Common Stock
Key Metrics
Market Snapshot
About
AEON Biopharma, Inc. (AEON) is a clinical stage biopharmaceutical company based in Irvine, California, best known for developing therapeutic treatments using botulinum toxins.
The company's primary asset is ABP-450 (prabotulinumtoxinA) injection, which it is developing for a range of debilitating medical conditions. Its clinical program is most advanced for neurological disorders. AEON has completed a Phase 2 study for ABP-450 in treating cervical dystonia, a painful condition causing involuntary neck muscle contractions. It also has an ongoing Phase 2 study evaluating the treatment for both chronic and episodic migraine. Beyond these areas, the company is developing ABP-450 for potential use in treating gastroparesis, which affects stomach emptying, and post-traumatic stress disorder.
AEON operates through strategic partnerships to advance its pipeline. It holds license agreements with Daewoong Pharmaceutical Co., LTD., and Viatris Inc., which provide foundational support for its development programs. As a clinical stage company, AEON does not yet have products approved for commercial sale, and its activities are focused on research, clinical trials, and regulatory advancement of its botulinum toxin-based therapeutic candidates.